Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAb-3F8 vs RA with GM-CSF in Refractory Neuroblastoma
NCT00969722Phase 2Terminated
- Sponsor
- United Therapeutics Corporation
- Start
- Aug 2009
- Primary completion
- Aug 2010
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of anti-GD2 monoclonal antibody 3F8 in neuroblastoma, sponsored by United Therapeutics Corporation. Started Aug 2009; status: terminated.
02
Drugs
anti-GD2 monoclonal antibody 3F8
03
Conditions
neuroblastoma
Beyond the preview
Go deeper on NCT00969722.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00969722.